STUDIES IN THYROID DISEASE

甲状腺疾病研究

• 批准号: 3876402
• 负责人: J ROBBINS
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3876402
• 关键词: cancer risk; combination cancer therapy; dosage; doxorubicin; drug adverse effect; endocrine disorder chemotherapy; hormone inhibitor; human subject; human therapy evaluation; hypothyroidism; iodine; lithium; mood disorders; neoplasm /cancer chemotherapy; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer radionuclide therapy; radiation dosage; radionuclide imaging /scanning; radiosensitizer; radiotracer; thyroid disorder; thyroid neoplasm; thyroxine; tissue /cell culture; triiodothyronine

Two forms of adjuvant therapy designed to improve the effectiveness of I-131 radiation in thyroid cancer are under study. The first is lithium ion, which is used to prolong the retention of I-131 in the cancer. Preliminary findings have been described in previous annual reports. The second is the use of doxorubicin (adriamycin) as a radiosensitizing agent. To evaluate its effectiveness, we have begun a randomized study of high-risk thyroid cancer patients who receive standard I-131 therapy with or without the administration of low-dose adriamycin (10mg/square m) 30 min preceding each I-131 treatment dose. To our knowledge, this is the first attempt to randomize patients in a therapy protocol for thyroid cancer employing I-131. Other patients with negative I-131 whole body scans but elevated concentration of thyroglobulin in blood are given I-131 therapy in an attempt to localize the cancer by post-therapy scanning. Most patients have been found to have positive post-therapy scans and they are under evaluation for possible beneficial effects of the therapy.

两种形式的辅助治疗，旨在提高有效性， 甲状腺癌的I-131辐射正在研究中。首先是锂 离子，其用于延长I-131在癌症中的保留。 初步调查结果已在以往的年度报告中作了说明。的 第二种是使用阿霉素（阿霉素）作为放射增敏剂。 为了评估其有效性，我们已经开始了一项随机研究， 接受标准I-131治疗的高危甲状腺癌患者， 或不给予小剂量阿霉素（10 mg/m2）30 min 在每次I-131治疗剂量之前。据我们所知，这是第一个 尝试在甲状腺癌治疗方案中随机分配患者 使用I-131。 其他I-131全身扫描阴性但升高的患者 血液中的甲状腺球蛋白浓度给予I-131治疗， 试图通过治疗后扫描定位癌症。大多数患者有 被发现有积极的治疗后扫描，他们是根据 评估治疗的可能有益效果。